Methods of treating psoriatic arthritis using il-17 antagonists
AssigneeNovartis AG
InventorsShephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
Life of this patent
Estimating the term…
Abstract
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
Claims28
A method of treating psoriatic arthritis (PsA), comprising:
- a) subcutaneously administering to a patient having PsA five doses of about 150 mg-about 300 mg of an IL-17 antibody, each of the five doses being delivered weekly;
- and
- b) thereafter, subcutaneously administering a dose of about 150 mg-about 300 mg of the IL-17 antibody to the patient every month, beginning one month from the fifth subcutaneous dose according to step a),
- wherein the IL-17 antibody binds to an epitope of the human IL-17 homodimer having two mature IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, 11e127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody has a KD of about 100-200 pM, and
- wherein the IL-17 antibody has an in vivo half-life of about 4 weeks.
A method of treating PsA, comprising:
- a) subcutaneously administering to a patient having PsA five doses of about 150 mg-about 300 mg of an IL-17 antibody, each of the five doses being delivered weekly;
- and
- b) thereafter, subcutaneously administering to the patient a dose of about 150 mg-about 300 mg of the IL-17 antibody every month, wherein the IL-17 antibody comprises:
- i) an immunoglobulin VH domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin VL domain comprising the amino acid sequence set forth as SEQ ID NO:10;
- ii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:1-3, respectively, and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively;
- or
- iii) an immunoglobulin VH domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:11-12, respectively, and an immunoglobulin VL domain comprising the hypervariable regions comprising the amino acid sequences set forth as SEQ ID NOs:4-6, respectively.
A method of treating PsA in a patient, comprising administering about 150 mg-about 300 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by 300 mg of secukinumab every 4 weeks.
A method of treating PsA in a patient, comprising administering about 150 mg-about 300 mg of secukinumab by subcutaneous injection to the patient at weeks 0, 1, 2, 3 and 4, followed by 300 mg of secukinumab monthly.
Dependencies are inferred from the claim text.